| Title |
Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy
|
|---|---|
| Published in |
Annals of Surgical Oncology, October 2015
|
| DOI | 10.1245/s10434-015-4921-5 |
| Pubmed ID | |
| Authors |
Shannon K. Swisher, Jose Vila, Susan L. Tucker, Isabelle Bedrosian, Simona F. Shaitelman, Jennifer K. Litton, Benjamin D. Smith, Abigail S. Caudle, Henry M. Kuerer, Elizabeth A. Mittendorf |
| Abstract |
Our group previously published data showing that patients could be stratified by constructed molecular subtype with respect to locoregional recurrence (LRR)-free survival after neoadjuvant chemotherapy and breast-conserving therapy (BCT). That study predated use of trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive patients. The current study was undertaken to determine the impact of subtype and response to therapy in a contemporary cohort. Clinicopathologic data from 751 breast cancer patients who received neoadjuvant chemotherapy (with trastuzumab if HER2(+)) and BCT from 2005 to 2012 were identified. Hormone receptor (HR) and HER2 status were used to construct molecular subtypes: HR(+)/HER2(-) (n = 369), HR(+)/HER2(+) (n = 105), HR(-)/HER2(+) (n = 58), and HR(-)/HER2(-) (n = 219). Actuarial rates of LRR were determined by the Kaplan-Meier method and compared by the log-rank test. Multivariate analysis was performed to determine factors associated with LRR. The pathologic complete response (pCR) rates by subtype were as follows: 16.5 % (HR(+)/HER2(-)), 45.7 % (HR(+)/HER2(+)), 72.4 % (HR(-)/HER2(+)), and 42.0 % (HR(-)/HER2(-)) (P < 0.001). Median follow-up was 4.6 years. The 5-year LRR-free survival rate for all patients was 95.4 %. Five-year LRR-free survival rates by subtype were 97.2 % (HR(+)/HER2(-)), 96.1 % (HR(+)/HER2(+)), 94.4 % (HR(-)/HER2(+)), and 93.4 % (HR(-)/HER2(-)) (P = 0.44). For patients with HR(-)/HER2(+) disease, the LRR-free survival rates were 97.4 and 86.7 % for those who did and those who did not experience pCR, respectively. For patients with HR(-)/HER2(-) disease, the LRR-free survival rates were 98.6 % (pCR) versus 89.9 % (no pCR). On multivariate analysis, the HR(-)/HER2(-) subtype, clinical stage III disease, and failure to experience a pCR were associated with LRR. Patients undergoing BCT after neoadjuvant chemotherapy have excellent rates of 5-year LRR-free survival that are affected by molecular subtype and by response to neoadjuvant chemotherapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 88 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 14% |
| Other | 11 | 13% |
| Student > Ph. D. Student | 10 | 11% |
| Student > Postgraduate | 9 | 10% |
| Researcher | 9 | 10% |
| Other | 14 | 16% |
| Unknown | 23 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 45 | 51% |
| Agricultural and Biological Sciences | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Business, Management and Accounting | 1 | 1% |
| Other | 5 | 6% |
| Unknown | 28 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 February 2019.
All research outputs
#6,292,300
of 22,831,537 outputs
Outputs from Annals of Surgical Oncology
#2,096
of 6,471 outputs
Outputs of similar age
#79,331
of 284,642 outputs
Outputs of similar age from Annals of Surgical Oncology
#17
of 93 outputs
Altmetric has tracked 22,831,537 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 6,471 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,642 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.